Loading...
•
Mar 31, 2024
Cullinan Oncology Q1 2024 Earnings Report
Announced first quarter 2024 financial results and provided a corporate update.
Key Takeaways
Cullinan Therapeutics reported its first quarter 2024 financial results, highlighting a strategic expansion into immunology with CLN-978, advancements in oncology programs, and a strong cash position extended into 2028 with a recent private placement. The company also appointed David Meek to its Board of Directors.
CLN-619 solid tumor dose escalation data to be presented at ASCO 2024.
CLN-978 development to focus on autoimmune diseases, starting with SLE.
Cash and investments totaled $434.8 million as of March 31, 2024, with additional proceeds extending runway into 2028.
David Meek appointed to Board of Directors.
Forward Guidance
Cullinan expects to complete enrollment in the pivotal Phase 2b portion of the REZILIENT1 study in patients with EGFR ex20ins NSCLC who have progressed after prior systemic therapy, with or without exon 20 targeted therapy, by year-end 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...